Literature DB >> 21506889

PDX1- and NGN3-mediated in vitro reprogramming of human bone marrow-derived mesenchymal stromal cells into pancreatic endocrine lineages.

Catarina Limbert1, Günter Päth, Regina Ebert, Veit Rothhammer, Moustapha Kassem, Franz Jakob, Jochen Seufert.   

Abstract

BACKGROUND AIMS: Reprogramming of multipotent adult bone marrow (BM)-derived mesenchymal stromal/stem cells (MSC) (BM-MSC) represents one of several strategies for cell-based therapy of diabetes. However, reprogramming primary BM-MSC into pancreatic endocrine lineages has not yet been consistently demonstrated.
METHODS: To unravel the role and interaction of key factors governing this process, we used well-characterized telomerase-immortalized human MSC (hMSC-TERT). Pancreatic endocrine differentiation in hMSC-TERT was induced by two major in vitro strategies: (i) endocrine-promoting culture conditions and (ii) ectopic expression of two master regulatory genes of the endocrine lineage, human neurogenin 3 (NGN3) and human pancreatic duodenal homeobox 1 (PDX1).
RESULTS: Both approaches triggered pancreatic endocrine gene expression, notably insulin, glucose-transporter 2 and somatostatin. Transgenic overexpression of NGN3 and/or PDX1 proteins not only induced direct target genes, such as NEUROD1 and insulin, and but also triggered parts of the gene expression cascade that is involved in pancreatic endocrine differentiation. Notably, ectopic NGN3 alone was sufficient to initiate the expression of specific beta-cell lineage-associated genes, most importantly PDX1 and insulin. This was demonstrated both transcriptionally by mRNA expression and reporter gene analyzes and at a protein level by Western blotting. Such reprogramming of hMSC-TERT cells induced glucose-insensitive insulin biosynthesis and secretion.
CONCLUSIONS: Our results indicate that establishment of glucose-dependent insulin secretion in partially reprogrammed human MSC may depend on additional maturation factors. Moreover, hMSC-TERT provides a suitable cell model for investigating further the molecular mechanisms of reprogramming and maturation of adult MSC towards pancreatic endocrine lineages.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21506889     DOI: 10.3109/14653249.2011.571248

Source DB:  PubMed          Journal:  Cytotherapy        ISSN: 1465-3249            Impact factor:   5.414


  17 in total

Review 1.  The use of β-cell transcription factors in engineering artificial β cells from non-pancreatic tissue.

Authors:  D Gerace; R Martiniello-Wilks; B A O'Brien; A M Simpson
Journal:  Gene Ther       Date:  2014-10-23       Impact factor: 5.250

2.  Characterization of vector-based delivery of neurogenin-3 in murine diabetes.

Authors:  Neil Phillips; Mark A Kay
Journal:  Hum Gene Ther       Date:  2014-04-14       Impact factor: 5.695

Review 3.  Mesenchymal stem cells in the treatment of type 1 diabetes mellitus.

Authors:  Jana Katuchova; Denisa Harvanova; Timea Spakova; Rastislav Kalanin; Daniel Farkas; Peter Durny; Jan Rosocha; Jozef Radonak; Daniel Petrovic; Dario Siniscalco; Meirigeng Qi; Miroslav Novak; Peter Kruzliak
Journal:  Endocr Pathol       Date:  2015-05       Impact factor: 3.943

4.  In vitro reprogramming of rat bmMSCs into pancreatic endocrine-like cells.

Authors:  Hong-Tu Li; Fang-Xu Jiang; Ping Shi; Tao Zhang; Xiao-Yu Liu; Xue-Wen Lin; Zhong-Yan San; Xi-Ning Pang
Journal:  In Vitro Cell Dev Biol Anim       Date:  2016-10-03       Impact factor: 2.416

5.  Engineered insulin secretion from neuroendocrine cells isolated from human thyroid.

Authors:  Peter M Thulé; Dingwu Jia; Susan Safley; Kereen Gordon; Graham Barber; Hong Yi; Soumya Nalli; Muhittin Onderci; Jyotirmay Sharma; John Shires; Collin J Weber
Journal:  World J Surg       Date:  2014-06       Impact factor: 3.352

6.  β-cell preservation and regeneration for diabetes treatment: where are we now?

Authors:  Michael J Karadimos; Archana Kapoor; Ilham El Khattabi; Arun Sharma
Journal:  Diabetes Manag (Lond)       Date:  2012-05-01

7.  Biologic and immunomodulatory properties of mesenchymal stromal cells derived from human pancreatic islets.

Authors:  Jaehyup Kim; Melissa J Breunig; Leah E Escalante; Neehar Bhatia; Ryan A Denu; Bridget A Dollar; Andrew P Stein; Summer E Hanson; Nadia Naderi; James Radek; Dermot Haughy; Debra D Bloom; Fariba M Assadi-Porter; Peiman Hematti
Journal:  Cytotherapy       Date:  2012-05-09       Impact factor: 5.414

8.  Adenoviral vectors stimulate glucagon transcription in human mesenchymal stem cells expressing pancreatic transcription factors.

Authors:  Arnaud Zaldumbide; Françoise Carlotti; Manuel A Gonçalves; Shoshan Knaän-Shanzer; Steve J Cramer; Bart O Roep; Emmanuel J H J Wiertz; Rob C Hoeben
Journal:  PLoS One       Date:  2012-10-26       Impact factor: 3.240

9.  A Short-activating RNA Oligonucleotide Targeting the Islet β-cell Transcriptional Factor MafA in CD34(+) Cells.

Authors:  Vikash Reebye; Pål Sætrom; Paul J Mintz; John J Rossi; Noriyuki Kasahara; Georgios Nteliopoulos; Joanna Nicholls; Abdelali Haoudi; Myrtle Gordon; Nagy A Habib
Journal:  Mol Ther Nucleic Acids       Date:  2013-06-04       Impact factor: 10.183

Review 10.  Mesenchymal stem/stromal cells as a delivery platform in cell and gene therapies.

Authors:  Naomi D'souza; Filippo Rossignoli; Giulia Golinelli; Giulia Grisendi; Carlotta Spano; Olivia Candini; Satoru Osturu; Fabio Catani; Paolo Paolucci; Edwin M Horwitz; Massimo Dominici
Journal:  BMC Med       Date:  2015-08-12       Impact factor: 8.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.